Type 2 Diabetes Mellitus and < em > Helicobacter pylori < /em > Eradication in a Clinical Population
CONCLUSIONS: H. pylori eradication rates do not differ by T2DM status, providing support for clinical trials of H. pylori eradication to reduce GC incidence among high-risk populations in the United States, such as individuals with T2DM.PMID:38569609 | PMC:PMC10997161 | DOI:10.14423/SMJ.0000000000001672
Source: Southern Medical Journal - Category: General Medicine Authors: Grace Sekaya Frances Wang HannahSofia Brown Priya Alagesan Bryan C Batch Katherine S Garman Meira Epplein Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Endoscopy | Gastric (Stomach) Cancer | Gastroenterology | General Medicine | Helicobacter Pylori | Insurance | USA Health